Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2017

Open Access 01-12-2017 | Research

The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature

Authors: Laurence W. Busse, Michael T. McCurdy, Osman Ali, Anna Hall, Huaizhen Chen, Marlies Ostermann

Published in: Critical Care | Issue 1/2017

Login to get access

Abstract

Background

Circulatory shock is a common syndrome with a high mortality and limited therapeutic options. Despite its discovery and use in clinical and experimental settings more than a half-century ago, angiotensin II (Ang II) has only been recently evaluated as a vasopressor in distributive shock. We examined existing literature for associations between Ang II and the resolution of circulatory shock.

Methods

We searched PubMed, MEDLINE, Ovid, and Embase to identify all English literature accounts of intravenous Ang II in humans for the treatment of shock (systolic blood pressure [SBP] ≤ 90 mmHg or a mean arterial pressure [MAP] ≤ 65 mmHg), and hand-searched the references of extracted papers for further studies meeting inclusion criteria. Of 3743 articles identified, 24 studies including 353 patients met inclusion criteria. Complete data existed for 276 patients. Extracted data included study type, publication year, demographics, type of shock, dosing of Ang II or other vasoactive medications, and changes in BP, lactate, and urine output. BP effects were grouped according to type of shock, with additional analyses completed for patients with absent blood pressure. Shock was distributive (n = 225), cardiogenic (n = 38), or from other causes (n = 90). Blood pressure as absent in 18 patients.

Results

For the 276 patients with complete data, MAP rose by 23.4% from 63.3 mmHg to 78.1 mmHg in response to Ang II (dose range: 15 ng/kg/min to 60 mcg/min). SBP rose by 125.2% from 56.9 mmHg to 128.2 mmHg (dose range: 0.2 mcg/min to a 1500 mcg bolus). A total of 271 patients with complete data were determined to exhibit a BP effect which was directly associated with Ang II. Subgroups (patients with cardiogenic, septic, and other types of shock) exhibited similar increases in BP. In patients with absent BP, deemed to be cardiac arrest, return of spontaneous circulation (ROSC) was achieved, and BP increased by an average of 107.3 mmHg in 11 of 18 patients. The remaining seven patients with cardiac arrest did not respond.

Conclusions

Intravenous Ang II is associated with increased BP in patients with cardiogenic, distributive, and unclassified shock. A role may exist for Ang II in restoring circulation in cardiac arrest.
Appendix
Available only for authorised users
Literature
1.
Gamper G, Havel C, Arrich J, Losert H, Pace NL, Mullner M, Herkner H. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2, CD003709.PubMed
2.
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–89.CrossRefPubMed
3.
Hiltebrand LB, Krejci V, Jakob SM, Takala J, Sigurdsson GH. Effects of vasopressin on microcirculatory blood flow in the gastrointestinal tract in anesthetized pigs in septic shock. Anesthesiology. 2007;106(6):1156–67.CrossRefPubMed
4.
Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–8.CrossRefPubMed
5.
Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313–9.CrossRefPubMed
6.
Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, De Backer D, Payen D. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med. 2006;34(3):589–97.CrossRefPubMed
7.
Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226–34.CrossRefPubMed
8.
Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–87.CrossRefPubMed
9.
Zhou F, Mao Z, Zeng X, Kang H, Liu H, Pan L, Hou PC. Vasopressors in septic shock: a systematic review and network meta-analysis. Ther Clin Risk Manag. 2015;11:1047–59.CrossRefPubMedPubMedCentral
10.
Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.CrossRefPubMedPubMedCentral
11.
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–30.CrossRefPubMed
12.
Campbell DJ. Do intravenous and subcutaneous angiotensin II increase blood pressure by different mechanisms? Clin Exp Pharmacol Physiol. 2013;40(8):560–70.CrossRefPubMed
13.
Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin ii and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44:1171–86.CrossRefPubMedPubMedCentral
14.
Oelkers W, Schoneshofer M, Schultze G, Brown JJ, Fraser R, Morton JJ, Lever AF, Robertson JI. Effect of prolonged low-dose angiotensin II infusion on the sensitivity of adrenal cortex in man. Circ Res. 1975;36(6 Suppl 1):49–56.CrossRefPubMed
15.
Conti C, Tranquilli AL, Garzetti GG, Romanini C. Modulation of vascular reactivity after acute calcium antagonist administration in pregnant women moderately sensitive to angiotensin infusion. Boll Soc Ital Biol Sper. 1994;70(10-11):243–8.PubMed
16.
Oney T, Kaulhausen H. The value of the angiotensin sensitivity test in the early diagnosis of hypertensive disorders in pregnancy. Am J Obstet Gynecol. 1982;142(1):17–20.CrossRefPubMed
17.
18.
19.
Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM, Yoo D, Dana SL, Chawla LS. Clinical eexperience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285–94.CrossRefPubMedPubMedCentral
20.
Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet. 1993;341(8846):703.CrossRefPubMed
21.
Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28(10):1165–8.CrossRefPubMed
22.
Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol. 1995;40(1):103–4.CrossRefPubMedPubMedCentral
23.
Tovar JL, Bujons I, Ruiz JC, Ibanez L, Salgado A. Treatment of severe combined overdose of calcium antagonists and converting enzyme inhibitors with angiotensin II. Nephron. 1997;77(2):239.CrossRefPubMed
24.
Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet. 1995;346(8990):1604.CrossRefPubMed
25.
Del Greco F, Johnson DC. Clinical experience with angiotensin II in the treatment of shock. JAMA. 1961;178:994–9.CrossRef
26.
Udhoji VN, Weil MH. Circulatory effects of angiotensin, levarterenol and metaraminol in the treatment of shock. N Engl J Med. 1964;270:501–5.CrossRefPubMed
27.
Cohn JN, Luria MH. Studies in clinical shock and hypotension. 3. Comparative effects of vasopressor drugs and dextran. Arch Intern Med. 1965;116(4):562–6.CrossRefPubMed
28.
Singh S, Malhotra RP. Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock). J Assoc Physicians India. 1966;14(11):639–45.PubMed
29.
Wallace JM, Lopez G, Malo-Camacho R, DeLeon JA, Walker JP, Kirksey TD, Derrick JR. Hemodynamic effects of angiotensin during surgical anesthesia. Am Heart J. 1967;73(3):326–33.CrossRefPubMed
30.
Eyraud D, Mouren S, Teugels K, Bertrand M, Coriat P. Treating anesthesia-induced hypotension by angiotensin II in patients chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg. 1998;86(2):259–63.PubMed
31.
Cohn JN, Luria MH. Studies in clinical shock and hypotension. ii. hemodynamic effects of norepinephrine and angiotensin. J Clin Invest. 1965;44:1494–504.CrossRefPubMedPubMedCentral
32.
Sorensen SS, Danielsen H, Jespersen B, Pedersen EB. Hypotension in end-stage renal disease: effect of postural change, exercise and angiotensin II infusion on blood pressure and plasma concentrations of angiotensin II, aldosterone and arginine vasopressin in hypotensive patients with chronic renal failure treated by dialysis. Clin Nephrol. 1986;26(6):288–96.PubMed
33.
Moore TJ, Lazarus JM, Hakim RM. Reduced angiotensin receptors and pressor responses in hypotensive hemodialysis patients. Kidney Int. 1989;36(4):696–701.CrossRefPubMed
34.
Nassif AC, Nolan TR, Corcoran AC. Angiotensin II in treatment of hypotensive states. JAMA. 1963;183:751–4.CrossRefPubMed
35.
36.
Beanlands DS, Gunton RW. Angiotensin ii in the treatment of shock following myocardial infarction. Am J Cardiol. 1964;14:370–3.CrossRefPubMed
37.
Belle MS, Jaffee RJ. The use of large doses of angiotensin in acute myocardial infarction with shock. J Lancet. 1965;85:193–4.PubMed
38.
Geary VM, Thaker UN, Chalmers PC, Sheikh F. The use of angiotensin II to treat profound hypotension in a patient taking amiodarone. J Cardiothorac Anesth. 1990;4(3):364–7.CrossRefPubMed
39.
Thaker U, Geary V, Chalmers P, Sheikh F. Low systemic vascular resistance during cardiac surgery: case reports, brief review, and management with angiotensin II. J Cardiothorac Anesth. 1990;4(3):360–3.CrossRefPubMed
40.
Thomas VL, Nielsen MS. Administration of angiotensin II in refractory septic shock. Crit Care Med. 1991;19(8):1084–6.CrossRefPubMed
41.
Ryding J, Heslet L, Hartvig T, Jonsson V. Reversal of 'refractory septic shock' by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest. 1995;107(1):201–3.CrossRefPubMed
42.
Antonucci E, Gleeson PJ, Annoni F, Agosta S, Orlando S, Taccone FS, Velissaris D, Scolletta S. Angiotensin II in refractory septic shock. Shock. 2017;47(5):560–6.CrossRefPubMed
43.
Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61(4):663–70.CrossRefPubMed
44.
Hall JE, Coleman TG, Guyton AC, Kastner PR, Granger JP. Control of glomerular filtration rate by circulating angiotensin II. Am J Phys. 1981;241(3):R190–7.
45.
Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Phys. 1984;246(6 Pt 2):F897–906.
46.
47.
Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96(11):4065–82.CrossRefPubMed
48.
Basu U, Seravalli J, Madayiputhiya N, Adamec J, Case AJ, Zimmerman MC. Rapid metabolism of exogenous angiotensin II by catecholaminergic neuronal cells in culture media. Physiol Rep. 2015;3(2).
49.
Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63(3):423–32.CrossRefPubMed
50.
Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, et al. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators. Circulation. 1993;88(2):481–91.CrossRefPubMed
51.
Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53–7.CrossRefPubMed
52.
van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106(3):367–72.CrossRefPubMed
53.
Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension. 2001;38(2):177–82.CrossRefPubMed
54.
Salgado DR, Rocco JR, Silva E, Vincent JL. Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach? Expert Opin Ther Targets. 2010;14(1):11–20.CrossRefPubMed
55.
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302.CrossRefPubMed
56.
Liu YJ, Shnkley NP, Welsh NJ, Black JW. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.CrossRef
57.
Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol. 1997;319(1):137–46.CrossRefPubMed
58.
McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol. 1999;39(6):547–59.CrossRefPubMed
59.
Wang G, Zhang Q, Yuan W, Wu J, Li C. Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation. Int J Mol Med. 2016;38(5):1463–73.CrossRefPubMedPubMedCentral
60.
Bjerregaard J, Jaffe RA. Intraoperative cardiac arrest: was it the ACE inhibitor? J Clin Anesth. 2014;26(1):62–4.CrossRefPubMed
61.
Dhingra R, Kirshenbaum LA. Negative inotropy by angiotensin II is mediated via phosphoinositide 3-kinase alpha-protein kinase C-coupled signaling pathway. Hypertension. 2010;56(3):349–50.CrossRefPubMed
62.
Liang W, Oudit GY, Patel MM, Shah AM, Woodgett JR, Tsushima RG, Ward ME, Backx PH. Role of phosphoinositide 3-kinase {alpha}, protein kinase C, and L-type Ca2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility. Hypertension. 2010;56(3):422–9.CrossRefPubMedPubMedCentral
63.
Clemson B, Gaul L, Gubin SS, Campsey DM, McConville J, Nussberger J, Zelis R. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest. 1994;93(2):684–91.CrossRefPubMedPubMedCentral
64.
Lyons D, Webster J, Benjamin N. Angiotensin II. Adrenergic sympathetic constrictor action in humans. Circulation. 1995;91(5):1457–60.CrossRefPubMed
65.
Paradis NA, Martin GB, Rivers EP, Goetting MG, Appleton TJ, Feingold M, Nowak RM. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA. 1990;263(8):1106–13.CrossRefPubMed
Metadata
Title
The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature
Authors
Laurence W. Busse
Michael T. McCurdy
Osman Ali
Anna Hall
Huaizhen Chen
Marlies Ostermann
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2017
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-017-1896-6

Other articles of this Issue 1/2017

Critical Care 1/2017 Go to the issue

Review

Pearls and pitfalls in comprehensive critical care echocardiography

Letter

Noninvasive ventilation in hypercapnic chronic obstructive pulmonary disease

Viewpoint

Individualized perfusion targets in hypoxic ischemic brain injury after cardiac arrest

Research

The common promoter polymorphism rs11666254 downregulates FPR2/ALX expression and increases risk of sepsis in patients with severe trauma

Research

Electrical impedance tomography for predicting failure of spontaneous breathing trials in patients with prolonged weaning

Review

The role of nutritional support in the physical and functional recovery of critically ill patients: a narrative review